{"id":"moxonidine","rwe":[{"pmid":"40649108","year":"2025","title":"Ten-Year Trend in the Potentially Inappropriate Prescribing of Renally-Dependent Medicines in Australian General Practice Patients with Dementia.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"40618547","year":"2025","title":"Imidazoline 1 receptors mediate the hyperthermia induced by preoptic agmatine application in male rats.","finding":"","journal":"Journal of thermal biology","studyType":"Clinical Study"},{"pmid":"40531792","year":"2025","title":"[Development of conditions for determination of imidazole derivatives in the blood using chromatography-mass spectrometry].","finding":"","journal":"Sudebno-meditsinskaia ekspertiza","studyType":"Clinical Study"},{"pmid":"40195776","year":"2025","title":"Potential of Combination Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes: Focus on Organ Protection.","finding":"","journal":"Kardiologiia","studyType":"Clinical Study"},{"pmid":"40007390","year":"2024","title":"GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME IN A BULGARIAN PATIENT: CASE REPORT AND SHORT PATHOGENETIC UPDATE IN RELATION TO THE CONNECTION TO ANTIGEN/ MOLECULAR MIMICRY.","finding":"","journal":"Georgian medical news","studyType":"Clinical Study"}],"tags":[{"label":"moxonidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Nischarin","category":"target"},{"label":"NISCH","category":"gene"},{"label":"ADRA2A","category":"gene"},{"label":"HTR1A","category":"gene"},{"label":"C02AC05","category":"atc"},{"label":"Active","category":"status"},{"label":"Essential hypertension","category":"indication"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":168.699,"date":"","count":230,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 230 times (LLR=169)"},{"llr":143.173,"date":"","count":76,"signal":"Product prescribing error","source":"DrugCentral FAERS","actionTaken":"Reported 76 times (LLR=143)"},{"llr":121.032,"date":"","count":147,"signal":"General physical health deterioration","source":"DrugCentral FAERS","actionTaken":"Reported 147 times (LLR=121)"},{"llr":113.768,"date":"","count":109,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 109 times (LLR=114)"},{"llr":97.176,"date":"","count":46,"signal":"Hypertensive crisis","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=97)"},{"llr":86.402,"date":"","count":45,"signal":"Labelled drug-drug interaction medication error","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=86)"},{"llr":78.88,"date":"","count":74,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=79)"},{"llr":77.49,"date":"","count":80,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=77)"},{"llr":63.282,"date":"","count":137,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 137 times (LLR=63)"},{"llr":60.345,"date":"","count":16,"signal":"Peripheral artery stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=60)"},{"llr":56.633,"date":"","count":10,"signal":"Benign gastrointestinal neoplasm","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=57)"},{"llr":53.398,"date":"","count":152,"signal":"Dizziness","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=53)"},{"llr":49.269,"date":"","count":21,"signal":"Product monitoring error","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=49)"},{"llr":48.653,"date":"","count":9,"signal":"Hyperkaliuria","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=49)"},{"llr":46.596,"date":"","count":32,"signal":"Electrolyte imbalance","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=47)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MOXONIDINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:59:16.733715+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:59:22.163091+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOXONIDINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:59:22.566802+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Nischarin agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:59:23.615417+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL19236/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:59:23.270904+00:00"}},"allNames":"moxonidin","offLabel":[],"synonyms":["moxonidine","normoxocin","moxonidin"],"timeline":[{"date":"1991-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1991-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Moxonidin","ecosystem":[{"indication":"Essential hypertension","otherDrugs":[{"name":"alacepril","slug":"alacepril","company":"Par Pharm"}],"globalPrevalence":1280000000}],"mechanism":{"target":"Nischarin","targets":[{"gene":"NISCH","source":"DrugCentral","target":"Nischarin","protein":"Nischarin"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"}],"modality":"Small Molecule","drugClass":"moxonidine","explanation":"","oneSentence":"","technicalDetail":"Moxonidine acts as an imidazoline receptor agonist, specifically targeting the I1 receptor, which is involved in the regulation of sympathetic nervous system activity. This leads to a decrease in the release of norepinephrine, a neurotransmitter that increases heart rate and blood pressure, resulting in a decrease in blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1856","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MOXONIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOXONIDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:03:58.638258","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:59:24.807722+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clonidine","drugSlug":"clonidine","fdaApproval":"1974-09-03","patentExpiry":"Sep 8, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"guanfacine","drugSlug":"guanfacine","fdaApproval":"1986-10-27","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"moxonidine","indications":{"approved":[{"name":"Essential hypertension","source":"DrugCentral","snomedId":59621000,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clonidine","brandName":"clonidine","genericName":"clonidine","approvalYear":"1974","relationship":"same-class"},{"drugId":"guanfacine","brandName":"guanfacine","genericName":"guanfacine","approvalYear":"1986","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04050410","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2019-08-27","conditions":["Postural Tachycardia Syndrome"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT04140721","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-31","conditions":["Postural Tachycardia Syndrome"],"enrollment":48,"completionDate":"2026-12-31"},{"nctId":"NCT05312892","phase":"PHASE1,PHASE2","title":"Sympathetic Mechanisms in Obesity-Crossover Design","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-20","conditions":["Obesity","Hypertension"],"enrollment":12,"completionDate":"2030-12-31"},{"nctId":"NCT04329806","phase":"PHASE1","title":"Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity","status":"TERMINATED","sponsor":"Italo Biaggioni","startDate":"2021-02-23","conditions":["Obesity-Associated Insulin Resistance"],"enrollment":10,"completionDate":"2022-07-27"},{"nctId":"NCT01094769","phase":"PHASE4","title":"Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Baker Heart and Diabetes Institute","startDate":"2011-04","conditions":["Diabetic Nephropathies"],"enrollment":48,"completionDate":"2020-04"},{"nctId":"NCT04479813","phase":"PHASE4","title":"Role of Sympathetic Activation in Ischemia Reperfusion Injury","status":"COMPLETED","sponsor":"Royal Perth Hospital","startDate":"2015-07-08","conditions":["Central Sympathetic Nervous System Diseases"],"enrollment":46,"completionDate":"2022-03-01"},{"nctId":"NCT04474899","phase":"PHASE4","title":"Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension","status":"UNKNOWN","sponsor":"Royal Perth Hospital","startDate":"2015-06-24","conditions":["Obesity","Hypertension"],"enrollment":120,"completionDate":"2024-06-24"},{"nctId":"NCT05147753","phase":"PHASE4","title":"Moxonidine Effects on Neuropeptide Y","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2010-01-11","conditions":["Obesity","Hypertension"],"enrollment":90,"completionDate":"2014-06-30"},{"nctId":"NCT02355821","phase":"NA","title":"Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women","status":"COMPLETED","sponsor":"National Research Center for Preventive Medicine","startDate":"2015-04","conditions":["Osteopenia","Arterial Hypertension"],"enrollment":114,"completionDate":"2018-07-10"},{"nctId":"NCT04023565","phase":"PHASE4","title":"Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Sergey V. Nedogoda","startDate":"2019-03-11","conditions":["Arterial Hypertension","Metabolic Syndrome"],"enrollment":120,"completionDate":"2020-12-30"},{"nctId":"NCT01567124","phase":"PHASE4","title":"Alleviating the Metabolic Side Effects of Antipsychotic Medications","status":"WITHDRAWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":["Schizophrenia"],"enrollment":0,"completionDate":""},{"nctId":"NCT01504321","phase":"PHASE4","title":"Polycystic Ovary Syndrome - Improving Outcomes","status":"COMPLETED","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-05","conditions":["Polycystic Ovary Syndrome"],"enrollment":42,"completionDate":"2015-12"},{"nctId":"NCT01791699","phase":"PHASE4","title":"Moxonidine for Prevention of Post-ablation AFib Recurrences","status":"COMPLETED","sponsor":"Spyridon Deftereos","startDate":"2012-08","conditions":["Atrial Fibrillation"],"enrollment":150,"completionDate":"2014-04"},{"nctId":"NCT01180231","phase":"PHASE4","title":"Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity","status":"UNKNOWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2010-09","conditions":["Obesity","Overweight"],"enrollment":77,"completionDate":"2014-09"},{"nctId":"NCT00518479","phase":"NA","title":"Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2003-09","conditions":["Hypertension","Left Ventricular Hypertrophy"],"enrollment":42,"completionDate":"2004-04"},{"nctId":"NCT01138423","phase":"PHASE4","title":"Treatment of Adiposity Related hypErTension (TARGET)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2010-08","conditions":["Hypertension","Abdominal Obesity","Metabolic Syndrome"],"enrollment":32,"completionDate":"2012-02"},{"nctId":"NCT01360710","phase":"PHASE4","title":"The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension","status":"UNKNOWN","sponsor":"Baker Heart and Diabetes Institute","startDate":"2012-01","conditions":["Abdominal Obesity","Hypertension"],"enrollment":100,"completionDate":""},{"nctId":"NCT00244504","phase":"PHASE3","title":"Moxonidine in Patients Undergoing Vascular Surgery","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2002-11","conditions":["Cardiac Disease","Vascular Surgery"],"enrollment":141,"completionDate":"2006-03"},{"nctId":"NCT00424801","phase":"NA","title":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-01","conditions":["Microvascular Angina","Hypertension"],"enrollment":10,"completionDate":"2008-12"},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":["Hypertension","Type 2 Diabetes"],"enrollment":440,"completionDate":""},{"nctId":"NCT00160277","phase":"PHASE3","title":"Efficacy and Safety of Moxonidine in Indian Patients","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2005-07","conditions":["Hypertension"],"enrollment":100,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006139","UNII":"CC6X0L40GW","CHEBI":"CHEBI:7009","INN_ID":"5207","RXNORM":"30257","UMLSCUI":"C0066837","chemblId":"CHEMBL19236","ChEMBL_ID":"CHEMBL19236","KEGG_DRUG":"D05087","DRUGBANK_ID":"DB09242","PUBCHEM_CID":"4810","SNOMEDCT_US":"318706009","IUPHAR_LIGAND_ID":"12574","MESH_SUPPLEMENTAL_RECORD_UI":"C043482"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.2 hours","clearance":"11.0 mL/min/kg","bioavailability":"88%","fractionUnbound":"0.93%","volumeOfDistribution":"1.8 L/kg"},"publicationCount":622,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C02AC05","allCodes":["C02AC05","C02LC05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul 4","pmid":"40649108","title":"Ten-Year Trend in the Potentially Inappropriate Prescribing of Renally-Dependent Medicines in Australian General Practice Patients with Dementia.","journal":"Journal of clinical medicine"},{"date":"2025 Jul","pmid":"40618547","title":"Imidazoline 1 receptors mediate the hyperthermia induced by preoptic agmatine application in male rats.","journal":"Journal of thermal biology"},{"date":"2025","pmid":"40531792","title":"[Development of conditions for determination of imidazole derivatives in the blood using chromatography-mass spectrometry].","journal":"Sudebno-meditsinskaia ekspertiza"},{"date":"2025 Mar 31","pmid":"40195776","title":"Potential of Combination Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes: Focus on Organ Protection.","journal":"Kardiologiia"},{"date":"2024 Dec","pmid":"40007390","title":"GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME IN A BULGARIAN PATIENT: CASE REPORT AND SHORT PATHOGENETIC UPDATE IN RELATION TO THE CONNECTION TO ANTIGEN/ MOLECULAR MIMICRY.","journal":"Georgian medical news"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1991","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1991-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:59:24.807722+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}